NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

Veracyte, Inc. (VCYT) Stock Analysis

Veracyte, Inc. (VCYT) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

VCYT

$42.53

−$2.14 (−4.79%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VCYT with… →

VCYT Key Statistics

As of Sep 4, 2026
Trading
Open
$44.21
Previous Close
$44.67
Day's Range
42.43–44.81
52-Week Range
29.46–60.91
Volume
992.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.93
Valuation
Market Cap
$3.42B
P/E Ratio
30.38
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
21.83
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.08
EPS (ttm)Profit attributable to each share over the last twelve months.
1.40
Financials (FY)
Revenue (FY)
$517.15M+16.01%
Net Income (FY)
$66.35M+174.89%
Profit marginThe share of revenue left as profit after all costs and taxes.
20.37%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
80.39M
1-Year Return
+34.93%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
1.34M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VCYT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+1.02%
2025+6.31%
2024+43.95%
2023+15.93%
2022−42.40%
2021−15.82%
2020+75.29%
2019+121.94%
2018+92.65%
2017−15.63%
2016 (partial year)+54.80%

As of September 4, 2026.

VCYT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$517.15M$66.35M12.8%
2024$445.76M$24.14M5.4%
2023$361.05M−$74.40M−20.6%
2022$296.54M−$36.56M−12.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$517.15M$362.53M$78.28M$66.35M12.8%
2024$445.76M$298.15M$19.51M$24.14M5.4%
2023$361.05M$229.68M−$17.45M−$74.40M−20.6%
2022$296.54M$175.68M−$35.34M−$36.56M−12.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VCYT Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricVCYTDiagnostics & Research medianvs median
P/E30.3833.088% below
P/S ratio6.084.9922% above
Profit margin20.37%0.00%20.4 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Veracyte, Inc. (VCYT) is capitalised at $3.42B on the latest close. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 755.

VCYT last closed at $42.53 on September 4, 2026. That is −$2.14 (−4.79%) against the previous close. Over the past 52 weeks the price has ranged from $29.46 to $60.91. The latest close sits 44.39% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $517.15M. That is +16.01% against the prior fiscal year, when revenue was $445.76M. The same year closed with net income of $66.35M. That is +174.89% against the prior fiscal year. Profit margin runs at 20.37%. That is 20.4 percentage points above the Diagnostics & Research median of 0%. Trailing earnings per share are 1.4.

Across the 4 fiscal years on file, revenue moves from $296.54M in 2022 to $517.15M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

VCYT trades at a trailing price-to-earnings ratio of 30.38. That is 8.16% below the Diagnostics & Research median of 33.08. On forward earnings the ratio is 21.83. The price-to-sales ratio is 6.08. On price-to-sales that is 21.93% above the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.93. Annualized volatility over the trailing 10 years is 62.72%. The trailing one-year price return is +34.93%. Across 10 years the annualized return works out at +22.37%.

Growth & Income

No dividend is on file for VCYT.

So far in 2026 the price is +1.02%. Across the complete calendar years on file, 2019 returned +121.94% and 2022 returned −42.40%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Veracyte, Inc. (VCYT) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Veracyte, Inc. VCYT $3.42B 30.4
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Veracyte, Inc. trades at a P/E of 30.4.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Veracyte, Inc.

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Visit website →